fa Clinical behaviour and long-term therapeutic response in orofacial granulomatosis patients treated with intralesional triamcinolone acetonide injections alone or in combination with topical pimecrolimus 1% بیماری های دهان Oral Medicine پژوهشي Research <p> <strong>Background: </strong></p><p>  Orofacial granulomatosis (OFG) is a relapsing inflammatory disorder of unknown aetiology and non-standardized treatment protocols. The aim of this study was to assess the clinical behaviour and long-term therapeutic response in OFG patients treated with intralesional triamcinolone acetonide (TA) injections alone or in combination with topical pimecrolimus 1%, as adjuvant, in those patients partially responders to TA. <strong></strong></p><p> <strong>Methods:</strong>  </p><p> We analysed data from 19 OFG patients followed-up for 7 years. Demographic characteristics, clinical behaviour and long-term therapeutic response were investigated. </p><p> <strong>Results:</strong></p><p>   Eleven (57.9%) OFG patients treated with intralesional TA injections therapy reached first complete clinical remission in a mean time of 10 ± 2.2 (95% CI, 8.5–11.5) weeks, while eight (42.1%) patients, partially responders to intralesional TA injections, were treated with TA injections plus topical pimecrolimus 1%, as adjuvant, achieving complete clinical remission in a mean time of 29.8 ± 7.8 (95% CI, 23.2–36.3) weeks. Relapses occurred in four TA responder patients with a disease-free time of 35.8 ± 8.7 (95% CI, 21.9–46.4) weeks and in five patients treated with TA and topical pimecrolimus 1% with a disease-free time of 55.8 ± 18.5 (95% CI, 32.8–78.8) weeks. Patients were followed-up for a mean time of 56.3 ± 18.2 (95% CI, 47.6–65.1) months. At last control, all 19 patients were in complete clinical remission. </p><p> <strong>Conclusion:</strong> </p><p>  These preliminary data suggest that intralesional TA injections still represent a mainstay in the treatment of OFG. It is unclear the role of topical pimecrolimus, as adjuvant, in leading OFG patients, partly responders to intralesional TA injections, to a complete clinical remission. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Pathology & Medicine</p><p> <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0714.2012.01186.x/abstract" target="_blank"><font color="#0000ff">Full Text</font></a></p> clinical response;OFG, orofacial granulomatosis;pimecrolimus;treatment;triamcinolone acetonide 0 0 http://idai.ir/browse.php?a_code=A-10-32-2219&slc_lang=fa&sid=1 Michele D. Mignogna mignogna@unina.it 100319475328460010454 100319475328460010454 Yes Oral Medicine Unit, Department of Odontostomatological and Maxillofacial Sciences, Federico II University of Naples, Naples, Italy Annamaria Pollio 100319475328460010455 100319475328460010455 No Oral Medicine Unit, Department of Odontostomatological and Maxillofacial Sciences, Federico II University of Naples, Naples, Italy Stefania Leuci 100319475328460010456 100319475328460010456 No Oral Medicine Unit, Department of Odontostomatological and Maxillofacial Sciences, Federico II University of Naples, Naples, Italy Elvira Ruoppo 100319475328460010457 100319475328460010457 No Oral Medicine Unit, Department of Odontostomatological and Maxillofacial Sciences, Federico II University of Naples, Naples, Italy Giulio Fortuna 100319475328460010458 100319475328460010458 No Oral Medicine Unit, Department of Odontostomatological and Maxillofacial Sciences, Federico II University of Naples, Naples, Italy/Department of Dermatology, Stanford University School of Medicine, Center for Clinical Sciences Research, Stanford, CA, USA